UBS Group AG Buys 154,673 Shares of MoonLake Immunotherapeutics $MLTX

UBS Group AG grew its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 183.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 239,020 shares of the company’s stock after acquiring an additional 154,673 shares during the quarter. UBS Group AG’s holdings in MoonLake Immunotherapeutics were worth $3,150,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in MLTX. FNY Investment Advisers LLC purchased a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at about $28,000. Bank of America Corp DE boosted its holdings in MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares in the last quarter. Covestor Ltd bought a new stake in MoonLake Immunotherapeutics in the 3rd quarter worth about $46,000. Finally, BNP Paribas Financial Markets increased its stake in MoonLake Immunotherapeutics by 18.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after buying an additional 1,158 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX stock opened at $18.19 on Monday. The company has a 50 day moving average of $17.42 and a 200-day moving average of $15.81. The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The firm has a market cap of $1.30 billion, a P/E ratio of -4.70 and a beta of 1.01.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.07). Sell-side analysts anticipate that MoonLake Immunotherapeutics will post -3.71 earnings per share for the current year.

Insider Activity at MoonLake Immunotherapeutics

In other news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the completion of the sale, the director owned 1,039,238 shares in the company, valued at $17,448,806.02. This trade represents a 78.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Da Silva Jorge Santos sold 51,873 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $18.23, for a total transaction of $945,644.79. Following the sale, the chief executive officer owned 2,924,893 shares of the company’s stock, valued at approximately $53,320,799.39. The trade was a 1.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 3,900,000 shares of company stock valued at $65,714,663. 12.02% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on MLTX shares. Zacks Research upgraded shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and increased their price objective for the company from $12.00 to $24.00 in a research note on Monday, March 23rd. HC Wainwright increased their price objective on shares of MoonLake Immunotherapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, Rothschild & Co Redburn upgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $12.00 to $40.00 in a research note on Thursday, March 19th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $23.85.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.